top of page
.png)
News
Melius receives Australian OGTR DIR licence to support first-in-human clinical trial of MMB-003
Melius MicroBiomics has received a DIR (Dealings Involving Intentional Release) licence from Australia's OGTR (Office of the Gene Technology Regulator), marking a key regulatory milestone as the company advances toward its first-in-human clinical trial in Australia. The DIR licence supports the planned clinical evaluation of MMB-003 (EcN:: ttr ), an investigational engineered microbial therapeutic being developed as a potential treatment for ulcerative colitis. This milestone
Mar 17
Tiny capsule, big impact: The BC breakthrough that could transform gut health
A recent article by Health Research BC featured Melius MicroBiomics. We are so grateful for the support from the Health Research BC...
Apr 8, 2025
Melius Signs Foundational Licensing Agreement with UBC
UBC announced that it finalized a licensing agreement with Melius for Melius' core GEMM™ (Genetically Engineered Microbial Medicine)...
Dec 3, 2024
Podcasts
Dr. Emeran Mayer with Sadhguru
Dr. Emeran Mayer with Neil deGrasse Tyson on StarTalk
Dr. Deanna Gibson with Dr. EmeranMayer on The Mind-Gut Conversation
Dr. Deanna Gibson on CRAM
Dr. Emeran Mayer on Big Think
Dr. Emeran Mayer with Sarah AnnMacklin on Live Well Be Well
Dr. Deanna Gibson | When Food Becomes Medicine
Dr. Deanna Gibson with Dr. Emeran Mayer on The Mind-Gut Conversation
Related Materials
The Mind-Gut Conversation with Emeran Mayer
Emeran Mayer with Sarah Ann Macklin on Live Well Be Well
Emeran Mayer with Neil deGrasse Tyson on StarTalk
Surface-functionalized bacteria: Frontier explorations in next-generation live biotherapeutics
Microbiota-directed biotherapeutics: considerations for quality and functional assessment
The Progression of Microbiome Therapeutics for the Management of Gastrointestinal Diseases and Beyond
Advancing microbiota therapeutics: the role of synthetic biology in engineering microbial communities for precision medicine
_edited.png)
bottom of page